Xeris Pharmaceuticals XERS
$16.97 +$0.35 (+2.11%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.00 +0.18%
Open$16.61
Prev close$16.62
Day range$16.53 – $17.04
Volume2.86M
Market cap$3.10B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±10.9%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+25.0%
Worst reaction-21.9%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 5 Nov 2026 | Pre Market | ±17.7% | +25.05% | Bigger than priced |
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±17.0% | -9.25% | Within range |
| 2026/Q1 | 7 May 2026 | Pre Market | ±15.7% | +4.08% | Within range |
| 2025/Q4 | 2 Mar 2026 | Pre Market | ±23.0% | -1.63% | Within range |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±14.6% | -21.88% | Bigger than priced |
| 2025/Q2 | 7 Aug 2025 | Pre Market | ±14.8% | +20.22% | Bigger than priced |
| 2025/Q1 | 8 May 2025 | Pre Market | ±17.6% | +15.18% | Within range |
| 2024/Q4 | 6 Mar 2025 | Pre Market | ±40.0% | +9.55% | Within range |
| 2024/Q3 | 8 Nov 2024 | Pre Market | ±32.4% | +3.27% | Within range |
| 2024/Q2 | 8 Aug 2024 | Pre Market | ±26.8% | +4.69% | Within range |
| 2024/Q1 | 9 May 2024 | Pre Market | ±30.3% | +1.62% | Within range |
| 2023/Q4 | 6 Mar 2024 | Pre Market | ±27.6% | -19.48% | Within range |
| 2023/Q3 | 9 Nov 2023 | Pre Market | ±37.9% | -8.84% | Within range |
| 2023/Q2 | 8 Aug 2023 | Pre Market | ±16.1% | +3.61% | Within range |
| 2023/Q1 | 9 May 2023 | Pre Market | ±14.6% | +13.75% | Within range |
| 2022/Q4 | 8 Mar 2023 | Pre Market | ±81.7% | -11.76% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q3
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$107.23M+44.2% YoY
Operating profit$16.92M+151.4% YoY
Net profit$11.29M+1,718.0% YoY
Diluted EPS$0.06
Free cash flow$35.31M+92.3% YoY
Operating cash flow$35.47M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
Return on equity-27.1%
Return on assets-1.6%
Return on invested capital6.0%
Current ratio2.15
Liabilities / assets88.5%
Cash & investments$131.08M
Total debt$219.72M
Net cash (debt)-$88.64M
Free cash flow / sales19.7%
No comments yet — be the first to weigh in on XERS.
Sign in to join the discussion.